Stock Research for ARRY

ARRY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARRY Stock Chart & Research Data

The ARRY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARRY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARRY Due diligence Resources & Stock Charts

The ARRY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARRY Detailed Price Forecast - CNN Money CNN View ARRY Detailed Summary - Google Finance
Yahoo View ARRY Detailed Summary - Yahoo! Finance Zacks View ARRY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ARRY Trends & Analysis - Trade-Ideas Barrons View ARRY Major Holders - Barrons
NASDAQ View ARRY Call Transcripts - NASDAQ Seeking View ARRY Breaking News & Analysis - Seeking Alpha
Spotlight View ARRY Annual Report - CompanySpotlight.com OTC Report View ARRY OTC Short Report - OTCShortReport.com
TradeKing View ARRY Fundamentals - TradeKing Charts View ARRY SEC Filings - Bar Chart
WSJ View Historical Prices for ARRY - The WSJ Morningstar View Performance/Total Return for ARRY - Morningstar
MarketWatch View the Analyst Estimates for ARRY - MarketWatch CNBC View the Earnings History for ARRY - CNBC
StockMarketWatch View the ARRY Earnings - StockMarketWatch MacroAxis View ARRY Buy or Sell Recommendations - MacroAxis
Bullish View the ARRY Bullish Patterns - American Bulls Short Pains View ARRY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ARRY Stock Mentions - StockTwits PennyStocks View ARRY Stock Mentions - PennyStockTweets
Twitter View ARRY Stock Mentions - Twitter Invest Hub View ARRY Investment Forum News - Investor Hub
Yahoo View ARRY Stock Mentions - Yahoo! Message Board Seeking Alpha View ARRY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ARRY - SECform4.com Insider Cow View Insider Transactions for ARRY - Insider Cow
CNBC View ARRY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARRY - OTC Markets
Yahoo View Insider Transactions for ARRY - Yahoo! Finance NASDAQ View Institutional Holdings for ARRY - NASDAQ


Stock Charts

FinViz View ARRY Stock Insight & Charts - FinViz.com StockCharts View ARRY Investment Charts - StockCharts.com
BarChart View ARRY Stock Overview & Charts - BarChart Trading View View ARRY User Generated Charts - Trading View




Latest Financial News for ARRY


Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
Posted on Wednesday July 18, 2018

It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.


Wired News - NCCN Recommends BRAFTOVI with MEKTOVI as Category 1 Treatment Option for BRAF-Mutant Melanoma
Posted on Tuesday July 17, 2018

LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want access to our free research report on Array BioPharma Inc. (NASDAQ: ARRY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARRY as the Company's latest news hit the wire. On July 13, 2018, the Company, which is a fully-integrated, biopharmaceutical Company, declared that the National Comprehensive Cancer Network (NCCN) has revised the Clinical Practice Guidelines in Oncology for Melanoma. The new guidelines make BRAFTOVI™ in combination with MEKTOVI® a Category 1 first-line and second-line treatment option for patients suffering with BRAFV600E, or BRAFV600K-mutant metastatic, or unresectable melanoma.


See what the IHS Markit Score report has to say about Array Biopharma Inc.
Posted on Saturday July 14, 2018

The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $1.26 billion.


The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Posted on Friday July 13, 2018

BOULDER, Colo. , July 13, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.